Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ultram Pain Indication Cannot Be Divided, J&J Says In Response To Teva

Executive Summary

The indication for Ultram (tramadol) cannot be divided into chronic versus acute pain to justify omission of patent-protected titration dosing from generic labeling, Johnson & Johnson told FDA

You may also be interested in...



36Ultram Generics Will Reference 50 mg, But Not 25 Mg, Titration Schedule

FDA is approving Ultram (tramadol) generics with labeling that includes the 50 mg titration regimen, but not the protected 25 mg titration schedule

36Ultram Generics Will Reference 50 mg, But Not 25 Mg, Titration Schedule

FDA is approving Ultram (tramadol) generics with labeling that includes the 50 mg titration regimen, but not the protected 25 mg titration schedule

Ultram Generic Approval For Acute Pain Would Avoid Protected Label – Teva

Teva is seeking approval for a generic version of Johnson & Johnson's Ultram (tramadol) only for acute pain in order to circumvent the brand's patent-protected titration schedule

Related Content

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel